inhibitory effects on CYP3A4 and CYP2J2 with FDA recommended probe substrates. Additionally, both amiodarone and dronedarone are known P-gp inhibitors. Hence, the concomitant administration of these anti-arrhythmic agents has the potential to augment the systemic exposure of rivaroxaban through simultaneous impairment of its clearance pathways. Currently, however, there is a lack of clinical data on the extent of these postulated DDIs. In this study, in vitro inhibition assays using rivaroxaban as the probe substrate demonstrated that both dronedarone and NDBD produced reversible inhibition as well as irreversible mechanism-based inactivation (MBI) of CYP3A4-and CYP2J2-mediated metabolism of rivaroxaban. However, amiodarone and NDEA were observed to cause reversible inhibition as well as MBI of CYP3A4 but not CYP2J2. Additionally, amiodarone, NDEA and dronedarone but not NDBD were determined to inhibit P-gp mediated rivaroxaban transport. The in vitro inhibition parameters were fitted into a mechanistic static model which predicted a 37% and 31% increase in rivaroxaban exposure due to the inhibition of hepatic and gut metabolism by amiodarone and dronedarone respectively. A separate model quantifying the inhibition of P-gp mediated efflux by amiodarone or dronedarone projected a 9% increase in rivaroxaban exposure. (Chugh et al., 2014) . As the prevalence of AF increases with age, the global burden of the disease is projected to increase exponentially, creating a significant public health burden (Rahman et al., 2014) . Therapeutic cornerstones of AF management include ventricular rate control, maintenance of sinus rhythm using antiarrhythmic therapy and prevention of stroke and systemic embolism using anticoagulants .
Rivaroxaban (Xarelto, Janssen Pharmaceuticals, Inc., Beerse Belgium), an inhibitor of Factor Xa of the coagulation cascade, was approved in 2011 as a novel non-Vitamin K oral anticoagulant. It is indicated for the reduction of risk of stroke and systemic embolism in patients with non-valvular AF (US FDA, 2011b). Studies have revealed that approximately two thirds of the administered rivaroxaban dose undergoes metabolic clearance in the liver, with contributions from cytochrome P450 (CYP) enzymes, namely CYP3A4, CYP2J2 and hydrolytic enzymes (Weinz et al., 2009) . The remaining one third of the given dose is eliminated in the urine largely via P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP [ABCG2]) mediated secretion (Gnoth et al., 2011) . A previous physiologically-based pharmacokinetic (PBPK) modeling study characterized a drug-drugdisease interaction, where the synergistic combination of renal impairment coupled with moderate CYP3A4 inhibition culminated in a clinically significant increase in rivaroxaban exposure (Grillo et al., 2012) . Outcomes of this simulation eventually led to recommendations cautioning against the concomitant administration of moderate CYP3A4/P-gp inhibitors with rivaroxaban in the presence of any degree of renal impairment (US FDA, 2011b) . This attests to the inherent susceptibility of rivaroxaban to complex drug-drug interactions (DDIs) mediated through simultaneous impairment of its multiple clearance pathways. Given its steep exposure-major bleeding relationship (US FDA, 2011a), it is thus imperative to identify clinical relevant DDI scenarios that could augment rivaroxaban exposure.
A subgroup analysis of the ROCKET AF trial studying the efficacy and safety of rivaroxaban highlighted the potential combination of antiarrhythmic drug therapy and anticoagulation as mainstays in AF management and concluded that the concomitant use of amiodarone and rivaroxaban warrants further investigation (Steinberg et al., 2014) . Dronedarone (Multaq, Sanofi Aventis, Bridgewater, NJ) was approved in 2009 as a structural analogue of amiodarone (US FDA, 2009a) . In a bid to minimize the extracardiac adverse effects associated with amiodarone, iodine substituents were eliminated to avoid amiodarone-linked thyroid toxicities and a methane-sulfonamide group was added to reduce tissue accumulation ( Fig. 1A and 1B 
1C)
and N-desbutyldronedarone (NDBD) (Fig. 1D) respectively (Fabre et al., 1993; Klieber et al., 2014) . Additionally, both drugs are substrates of CYP2J2 (Lee et al., 2010; Karkhanis et al., 2016) .
The common structural features in these antiarrhythmic agents and their metabolites are the alkylamine and furan that are in turn associated with mechanism-based inactivation (MBI) of CYP450 (Orr et al., 2012) . Indeed, corroborating previous findings, our laboratory established the reversible and irreversible inhibition of CYP3A4-and CYP2J2-mediated metabolism of US FDA recommended probe substrates by amiodarone and NDEA (Ohyama et al., 2001; McDonald et al., 2015; Karkhanis et al., 2016) as well as dronedarone and NDBD (Hong et al., 2015; Karkhanis et al., 2016) .
Independently, amiodarone and dronedarone have been reported as P-gp inhibitors (US FDA, 2009b , 2012 Table 1 ). Inactivation of CYP3A4 (40 pmol/mL) and CYP2J2 (20 pmol/mL) by dronedarone (0-2.5 µM) and NDBD (0-5 µM) was investigated using the same two step incubation protocol except with a 10-fold dilution into the secondary incubation. 
In Equation 1, k inact represents the maximum inactivation rate constant at infinite inactivator concentration; K I is the concentration of inactivator at the half-maximum rate of inactivation and [I] is the in vitro inactivator concentration.
Inhibition of P-gp efflux of rivaroxaban by amiodarone, dronedarone and their metabolites.
Madin-Darby canine kidney sub-clone I cells transfected with multi drug resistance protein 1 (MDCK-MDR1) were maintained in DMEM culture media supplemented with 10% FBS, Lglutamine (862 mg/L) and 1% penicillin/streptomycin. For transport studies, cells were first seeded at a density of 250,000 cells/well and culture media was refreshed after 24 h. At approximately 48 h post-seeding, culture media was first removed and each well and insert were rinsed gently with PBS to ensure no residual metabolic waste. Test inhibitors were dissolved in methanol whereas rivaroxaban was reconstituted in ACN and dimethyl sulfoxide (DMSO) at lower (2 mM) and higher concentration (20 mM) levels respectively. Dilutions for all compounds were carried out using ACN.
Triplicate sets of wells were used to assess the apparent permeability of rivaroxaban from the apical (A) to basolateral (B) chambers [P app (A B)] and B to A [P app (B A)]. To initiate transport, the donor solution was first added followed by the receiver solution. All experiments were carried out at room temperature (24 ± 1°C). Amprenavir (10 µM) and propranolol (25 µM) were used as positive
1 2 controls (substrate and inhibitor respectively). P app (A→B) of lucifer yellow (100 µM) was utilized as a marker of monolayer integrity. The fluorescence of lucifer yellow of each apical and basolateral solution was measured at an excitation wavelength of 430 nm and emission wavelength of 540 nm using a Tecan Infinite ® F500 plate reader (Männedorf, Switzerland). Acceptance criterion for a confluent monolayer was defined as lucifer yellow permeability of less than 80 nm/s.
To ensure P-gp assay sensitivity, experiments were first performed to investigate the potential for both concentration and time-dependent saturation of the transport of rivaroxaban via P-gp (Supplemental Methods). The optimal incubation time was eventually determined to be 90 min and a rivaroxaban concentration of 10 µM was also selected (Supplemental Fig. 1 and 2 ). Subsequently, 25 and 12.5 µM of each inhibitor (i.e. amiodarone, dronedarone, NDEA and NDBD) were first subjected to a preliminary study to estimate their IC 50 values. The inhibitor concentrations were subsequently optimized to encompass the IC 50 and ensure inhibition assay sensitivity. The receiver solution was collected and stored at -20°C for further sample processing prior to LC/MS/MS analysis (Supplemental Methods). In order to determine the mode of P-gp inhibition, 3 inhibitor concentration levels in proximity of the IC 50 value were assayed against 2 concentration levels of rivaroxaban (5 and 20 µM). A Dixon plot was generated to predict the mode of P-gp inhibition as well as determine the K i values.
Estimating the extent of metabolic DDI using a mechanistic static model. The kinetic constants accounting for reversible inhibition (i.e. K i ) and time-dependent inactivation (i.e k inact , K I ) of the drug metabolizing enzymes were incorporated into a mechanistic static model developed previously by
Fahmi et al (Fahmi et al., 2008) and refined by Isoherranen et al (Isoherranen et al., 2012) to account for multi P450 inhibition. The proposed model accounts for the contributions of enzyme inhibition both in the liver and within the gut wall in predicting the extent of DDI. The area under the curve ratio (AUCR) in the presence of a pharmacokinetic DDI is described by Equation 2.
The terms are defined as follows:
A is the term for time-dependent inactivation observed in the liver for each of the P450 enzymes inactivated,
B is the term for reversible inhibition in the liver for each of the P450 enzymes inactivated,
X is the term for time-dependent inactivation of CYP3A4 observed in the intestine, Table 1 ). The degradation rates for CYP3A4 in the liver (k deg,H ) and intestine (k deg,G ) were 0.00032 and 0.00048 min -1 based on t 1/2 of 36 h and 24 h (Fahmi et al., 2008) .
For CYP2J2, there is insufficient clinical pharmacokinetic data to perform similar calculations. As a result, the average of the calculated estimates for the various hepatic CYP enzymes (0.00026 min -1 ) was used (Yang et al., 2008) . The fraction of rivaroxaban metabolized by CYP3A4 (f m,CYP3A4 ) and CYP2J2 (f m,CYP2J2 ) has been reported to be 0.18 and 0.14 respectively (Mueck et al., 2014) on plasma exposure of the victim drug (Feng et al., 2013) . The AUC ratio of the victim drug in the presence and absence of the inhibitor is summarized in Equation 3.
where [I] represents the maximum plasma concentration of the inhibitor ( Table 1) . The net secretory clearance of rivaroxaban (CL sec.c ) (55.6 mL/min) was approximated to be five sixth of total plasma renal clearance (66.7 mL/min) (Mueck et al., 2014) . The total plasma clearance (CL) of rivaroxaban has been reported to be 166.7 mL/min and is a composite of the hepatic and renal clearances (Mueck et al., 2014) .
RESULTS

Reversible
Inhibition of CYP3A4 and CYP2J2 by amiodarone, dronedarone and their metabolites. The reversible inhibition of CYP3A4 and CYP2J2 by amiodarone, dronedarone and their metabolites was investigated using the peak area of rivaroxaban metabolite as a proxy for the rate of product formation. Rivaroxaban was evaluated across 5 concentration levels spanning its K m in the presence of varying concentrations of amiodarone, dronedarone, NDEA and NDBD. In a preliminary study of reversible inhibition of CYP2J2 by amiodarone and NDEA, high concentrations of both amiodarone and NDEA were easily overcome by a small increase in rivaroxaban concentration, thus suggesting that amiodarone and NDEA did not inhibit CYP2J2 with rivaroxaban as the probe substrate (Supplemental Fig. 3A) . However, based on the inhibition kinetics plots ( Fig.   2A-B) and their respective Lineweaver Burk plots (Fig. 2C-D) , dronedarone and NDBD were established to be mixed competitive inhibitors of CYP2J2 when rivaroxaban was used as the probe substrate. On the other hand, amiodarone and NDEA exhibited mixed competitive inhibition of CYP3A4 (Fig. 3A-B and 3E-F) whereas dronedarone and NDBD demonstrated competitive inhibition ( Fig. 3C-D and 3G-H) . The calculated inhibition constants K i of the relevant inhibitors against the respective enzymes are presented in Table 2 .
Time-and concentration-dependent inactivation of CYP3A4 and CYP2J2 by amiodarone, dronedarone and their metabolites. To investigate the MBI of CYP3A4 and CYP2J2 by amiodarone, dronedarone and their metabolites, rivaroxaban was used as the probe substrate and the rate of hydroxylation at the morpholinone moiety of rivaroxaban was monitored and used as a surrogate for enzymatic activity. In the presence of NADPH, a time-dependent decrease in CYP2J2 enzymatic activity was not observed when pre-incubated with amiodarone (5 µM and 50 µM) and NDEA (Supplemental Fig. 3B and 3C) . calculated from various concentrations of dronedarone ( Fig. 4A) and NDBD (Fig. 4B ) followed saturation kinetics that approached a maximum rate of inactivation ( Fig. 4C-D) . Likewise, as presented in Fig. 5A-D , time-and concentration-dependent inactivation of CYP3A4 were established for both amiodarone, dronedarone and their metabolites. Kinetic plots (k obs versus inactivator concentration) also demonstrated saturation kinetics (Fig. 5E-H) . Calculated inactivation kinetic parameters, K I and k inact , are summarized in Table 3 . The efficiency of enzyme inactivation (k inact /K I ratio) is also reported.
Cell Monolayer Integrity and Compound Recovery. A-to-B flux determinations of lucifer yellow
were used to confirm monolayer integrity when co-incubated with the highest concentration levels of the test substrate and inhibitors. This data confirmed that the monolayer was intact under these extreme conditions and validated its suitability for subsequent permeability studies. Using LLE, high recovery of rivaroxaban ~ 100 % and accurate linear calibration (+/-20 % accuracy and r 2 0.99) were achieved reproducibly from 0.01-10 µM. For rivaroxaban concentrations above 10 µM, saturation of the detector was observed and the samples were diluted using DMEM before sample processing in order to ensure its accurate quantitation. Percentage recovery of rivaroxaban from the apical and basolateral chambers at the end of the assay (mass balance) was greater than 80%, indicating that no significant amount of rivaroxaban was lost during sample transfer and processing nor in MDCK-MDR1, hence demonstrating the reliability of measured P app values.
P-gp inhibitory IC 50 and K i of test inhibitors. The concentration-dependent inhibitory effect of
amiodarone, dronedarone and their metabolites on transport of rivaroxaban across MDR1-MDCKII monolayers was tested. IC 50 is the inhibitor concentration needed to decrease the efflux ratio by half.
Amiodarone (Fig. 6A) and NDEA (Fig. 6B) yielded similar IC 50 values of 10.3 µM and 9.20 µM respectively. Based on an IC 50 of 1.83 µM (Fig. 6C) , dronedarone was determined to be the most potent P-gp inhibitor while NDBD demonstrated little P-gp inhibition activity as seen from its high IC 50 value of 76.3 µM (Fig. 6D) . Subsequently, the respective inhibitory concentrations that produced This article has not been copyedited and formatted. The final version may differ from this version. 
DISCUSSION
The application of in vitro methodologies to evaluate the inhibitory potential of a drug entity and assess the likelihood of in vivo drug interactions is a critical aspect of the drug development and regulatory review paradigm (Zhang et al., 2009) . In this study, we quantified the in vitro inhibition parameters to characterize the DDI between rivaroxaban and the antiarrhythmic agents.
Rivaroxaban was not tested as a substrate in previous in house studies investigating the CYP3A4 and CYP2J2 inhibitory potencies of amiodarone, dronedarone and their metabolites (Hong et al., 2015; Karkhanis et al., 2016) . In this study, we observed a significantly slower rate of rivaroxaban clearance by CYP3A4 as compared to CYP2J2 during initial assay optimization (data not published). Our optimization culminated in two incubation time periods of 2 h and 30 min for the sensitive detection of inhibitory effects against CYP3A4 and CYP2J2 respectively.
We report for the first time the competitive inhibition as well as MBI of CYP3A4 and CYP2J2 by dronedarone and NDBD with rivaroxaban as the probe substrate. On the other hand, amiodarone and NDEA demonstrated mixed competitive inhibition of CYP3A4 but not CYP2J2. Similarly, MBI was established for amiodarone and NDEA with respect to CYP3A4 but not CYP2J2. Based on our reported K i values ( Table 2) , both amiodarone and NDEA exhibited similar potencies for mixed competitive inhibition against CYP3A4 whereas dronedarone is a relatively more potent inhibitor of both CYP3A4 and CYP2J2 as compared to NDBD. For MBI, our results confirmed that the inactivation efficiency of NDEA was approximately threefold higher than that of amiodarone against CYP3A4 (Table 3) . Between dronedarone and NDBD, dronedarone exhibited a stronger inactivation efficiency against CYP3A4 compared to NDBD while both dronedarone and NDBD demonstrated comparable CYP2J2 inactivation efficiency (Table 3) .
Using two concentrations of rivaroxaban as the test substrate, our monolayer efflux studies also illustrated the non-competitive allosteric inhibition of P-gp mediated rivaroxaban efflux by amiodarone. This finding corroborated previous in silico studies which also predicted amiodarone to inhibit P-gp by noncompetitive allosteric inhibition (Seelig and Landwojtowicz, 2000) . Based on the structural similarities of NDEA to amiodarone, NDEA was assumed to follow a similar mode of P-gp inhibition. Intriguingly, although dronedarone was determined to be a competitive inhibitor of P-gp efflux, NDBD demonstrated a minimal inhibitory effect on P-gp ( ) was consistent with previous in vitro studies using midazolam as a probe substrate (McDonald et al., 2015) . Likewise, NDEA (K i : 5.36 µM) being more potent than amiodarone (K i : 8.94 µM) in the inhibition of P-gp mediated rivaroxaban transport was also well aligned with previous transport assays using digoxin as a probe substrate (Katoh et al., 2001) . In summary, it is evident that a holistic prediction of in vivo clinical DDI would require consideration of the combined inhibitory effects of both the parent compound and its metabolite.
Comparison of inactivation parameters obtained in our study with previous in house data generated using US FDA validated probe substrates established a probe substrate differential response (Supplemental Table 3 ). In the case of CYP3A4, the inactivation efficiency (k inact /K I ) of dronedarone and NDBD was greater when rivaroxaban was used as the probe substrate (i.e. 185 and 53.7 min 2 0 substrate-dependent inhibition profiles has been emphasized mainly for CYP3A4, which possesses multiple probe substrate binding regions within its active site (Kenworthy et al., 1999) . Consequently, the interactions observed with one CYP3A4 probe may not accurately reflect those observed with another probe substrate (Galetin et al., 2005; Foti et al., 2010) . Although CYP2J2 metabolism is generally restricted to a single active site, our findings suggested differential binding and metabolism among different substrates. Previous studies utilizing US FDA recommended astemizole demonstrated both reversible and irreversible inhibition of CYP2J2 metabolism by amiodarone (Lee et al., 2012) . However, our investigation revealed that amiodarone did not inhibit CYP2J2 reversibly and irreversibly with rivaroxaban as the probe substrate (Supplemental Figures 3A-B) , suggesting the possibility of independent access of the active site of CYP2J2 by amiodarone and rivaroxaban (Shou et al., 1994) .
Taken together, our study (1) reiterates that the variability of in vitro inhibitory potencies against CYP3A4 and CYP2J2 is highly dependent on the choice of probe substrates and (2) confirms the importance of using specific victim drug as the probe substrate in enzyme and transporter interaction studies.
In our study, the static prediction of DDI between amiodarone, dronedarone and rivaroxaban yielded an AUC fold change of 1.22 and 1.17 respectively when inhibition of hepatic metabolism was considered ( Table 4) . Based on US FDA's guidelines (Table 5 ) (US FDA, 2012) , this would imply that no significant inhibition was present. However, upon inclusion of gut metabolism, amiodarone and dronedarone were predicted to precipitate an AUC fold change in rivaroxaban exposure by 1.37 and 1.31 respectively. This attests to the significance of intestinal wall metabolism (Galetin et al., 2007) which when ignored can under-estimate the extent of DDIs involving CYP3A4. Additionally, our results underscore the potential contribution of NDEA and NDBD to the eventual DDI magnitude,
where AUC fold changes of 1.22 and 1.26 were observed respectively. Furthermore, the inhibition of P-gp mediated rivaroxaban efflux by amiodarone, NDEA and dronedarone was also predicted to independently produce AUC ratio increases of 1.09, 1.13 and 1.09 respectively. However, the (Fahmi et al., 2008 ). Yet, in our case, our model cannot be cross-validated since clinical interaction data between rivaroxaban and amiodarone or dronedarone is not available. Nevertheless, it has been shown that model predictability was optimal when free portal steady state C max was used for the reversible inhibition portion of the expression (term B) and free systemic steady state C max was used for the time-dependent inactivation portion (term A) (Fahmi et al., 2009) . Hence, these validated estimates of
[I] in vivo were adopted in our study to enhance DDI predictability.
Given that the in vitro interactions might culminate in a more significant DDI than that estimated using mechanistic static modeling, the use of PBPK models present several theoretical advantages.
First, PBPK modeling utilizes a dynamic approach that allows consideration of changes in concentrations of enzyme, substrate and inactivator/inhibitor with time instead of relying on static point estimates. Second, PBPK modeling allows the evaluation of both intrinsic (e.g., organ dysfunction, age, genetics) and extrinsic (e.g., drug-drug interactions) factors, alone or in combinations, on drug exposure. Third, DDIs across multiple pathways and the variability of these DDIs in different populations can be examined.
Another factor that could potentially affect the in vitro to in vivo correlation is the presence of nonspecific protein binding. The K i , K I and k inact values were computed without accounting for protein binding in the recombinant system. Yet, Ishigam et al. has reported how the conversion of inhibition constants to their unbound values could eventually lead to more accurate predictions of the AUC-fold change upon co-administration of drugs (Ishigam et al., 2001) . Furthermore, considering the high protein binding of amiodarone, dronedarone and their metabolites, the derived in vitro inhibition and inactivation parameters might be relatively higher when unbound concentrations are considered.
Hence, to increase confidence in the DDI prediction, the fraction unbound in each incubation should be determined either computationally (Austin et al., 2002) or through equilibrium dialysis experiments (Banker et al., 2003) .
In conclusion, amiodarone, dronedarone, NDEA and NDBD cause reversible inhibition and 
